Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Idarubincin and Amufostine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Idarubicin plus amifostine |
| 2 | EXPERIMENTAL | Idarubincin |
| Name | Type | Description |
|---|---|---|
| Idarubincin and Amufostine (Ethyol) | DRUG | Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36) |
| Idarubincin | DRUG | Idarubincin (12mg/m2) and ara-C(N-18) |
Inclusion Criteria: * Adult men and women of at least 60 years of age at the time of entry or randomization; * Histologically proven AML with at least 20% myeloblasts based on bone marrow aspiration and biopsy performed within 5 days prior to entry or randomization; History of prior MDS allowed pro...
Top 20 of 63 competitors
Idarubincin and Amufostine is an investigational combination therapy being studied for the treatment of leukemia, specifically acute myeloid leukemia, in older patients aged 60 years and above. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Idarubincin and Amufostine is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate this combination therapy for the treatment of leukemia.
Idarubincin and Amufostine is in Phase 1 clinical development. It is an investigational drug combination that has not yet received regulatory approval. The Phase 1 trial has been completed, and the therapy remains under investigation for its safety and efficacy in treating leukemia.
Idarubincin and Amufostine has been studied in one clinical trial with the identifier NCT00086099. This Phase 1 study evaluated the addition of amifostine to idarubicin and cytosine arabinoside in older patients with acute myeloid leukemia. The trial was completed and enrolled 54 participants in the United States and Israel.
Idarubincin and Amufostine refers to a combination therapy that includes amifostine and idarubicin, along with cytosine arabinoside. The clinical trial NCT00086099 evaluated the addition of amifostine to a regimen of idarubicin and cytosine arabinoside in older patients with acute myeloid leukemia.